Trevena (TRVN) Sees Large Volume Increase

Trevena Inc (NASDAQ:TRVN) saw strong trading volume on Friday . 1,798,098 shares traded hands during trading, an increase of 81% from the previous session’s volume of 994,718 shares.The stock last traded at $1.63 and had previously closed at $1.51.

Several equities research analysts recently weighed in on the stock. HC Wainwright cut their target price on shares of Trevena from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Barclays downgraded shares of Trevena from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $15.00 to $2.50 in a research note on Monday, October 16th. Oppenheimer set a $5.00 target price on shares of Trevena and gave the stock a “buy” rating in a research note on Thursday, October 12th. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Wednesday, October 18th. Finally, Needham & Company LLC cut their target price on shares of Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $7.35.

The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92. The firm has a market capitalization of $90.14, a PE ratio of -0.99 and a beta of -0.51.

Large investors have recently made changes to their positions in the business. Nationwide Fund Advisors increased its position in shares of Trevena by 92.1% in the 2nd quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 23,557 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Trevena by 51.9% in the 2nd quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 18,900 shares during the last quarter. Virtu KCG Holdings LLC increased its position in shares of Trevena by 144.0% in the 2nd quarter. Virtu KCG Holdings LLC now owns 58,660 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 34,618 shares during the last quarter. Rhumbline Advisers increased its position in shares of Trevena by 30.1% in the 2nd quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 14,880 shares during the last quarter. Finally, American Century Companies Inc. purchased a new stake in shares of Trevena in the 4th quarter valued at approximately $135,000. 56.74% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/02/09/trevena-trvn-sees-large-volume-increase.html.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit